AU2003233116B2 - Active complex of alpha-lactalbumin (hamlet) and cofactor - Google Patents

Active complex of alpha-lactalbumin (hamlet) and cofactor Download PDF

Info

Publication number
AU2003233116B2
AU2003233116B2 AU2003233116A AU2003233116A AU2003233116B2 AU 2003233116 B2 AU2003233116 B2 AU 2003233116B2 AU 2003233116 A AU2003233116 A AU 2003233116A AU 2003233116 A AU2003233116 A AU 2003233116A AU 2003233116 B2 AU2003233116 B2 AU 2003233116B2
Authority
AU
Australia
Prior art keywords
lactalbumin
use according
human
biologically active
bovine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003233116A
Other languages
English (en)
Other versions
AU2003233116A1 (en
Inventor
Catherine Svanborg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamlet Pharma AB
Original Assignee
Hamlet Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamlet Pharma AB filed Critical Hamlet Pharma AB
Publication of AU2003233116A1 publication Critical patent/AU2003233116A1/en
Assigned to HAMLET PHARMA AB reassignment HAMLET PHARMA AB Request for Assignment Assignors: SVANBORG, CATHERINE
Assigned to NYA HAMLET PHARMA AB reassignment NYA HAMLET PHARMA AB Request for Assignment Assignors: HAMLET PHARMA AB
Application granted granted Critical
Publication of AU2003233116B2 publication Critical patent/AU2003233116B2/en
Assigned to HAMLET PHARMA AB reassignment HAMLET PHARMA AB Request for Assignment Assignors: NYA HAMLET PHARMA AB
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2003233116A 2002-05-08 2003-05-08 Active complex of alpha-lactalbumin (hamlet) and cofactor Ceased AU2003233116B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0210464.4A GB0210464D0 (en) 2002-05-08 2002-05-08 Therapeutic treatment
GB0210464.4 2002-05-08
PCT/IB2003/002366 WO2003095490A1 (en) 2002-05-08 2003-05-08 Active complex of alpha-lactalbumin (hamlet) and cofactor

Publications (2)

Publication Number Publication Date
AU2003233116A1 AU2003233116A1 (en) 2003-11-11
AU2003233116B2 true AU2003233116B2 (en) 2009-03-26

Family

ID=9936230

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003233116A Ceased AU2003233116B2 (en) 2002-05-08 2003-05-08 Active complex of alpha-lactalbumin (hamlet) and cofactor

Country Status (8)

Country Link
US (2) US7270822B2 (enExample)
EP (1) EP1506233B8 (enExample)
JP (1) JP2006500321A (enExample)
AU (1) AU2003233116B2 (enExample)
CA (1) CA2485223A1 (enExample)
DK (1) DK1506233T3 (enExample)
GB (1) GB0210464D0 (enExample)
WO (1) WO2003095490A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210464D0 (en) * 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
EP1727561A1 (en) * 2004-02-26 2006-12-06 HAMLET Pharma AB Lactalbumin for inhibiting angiogenesis
GB0408752D0 (en) * 2004-04-20 2004-05-26 Hamlet Ltd Therapeutic treatment
EP1715334A1 (fr) * 2005-04-22 2006-10-25 Adamant Technologies SA Procédé utilisant un capteur électrochimique et électrodes formant ce capteur
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
WO2009135494A2 (en) * 2008-05-09 2009-11-12 Nya Hamlet Pharma Ab Alpha-lactalbumin composition for the treatment of actinic keratosis
WO2010131237A1 (en) * 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
JP2961625B2 (ja) 1991-01-21 1999-10-12 雪印乳業株式会社 α−ラクトアルブミン含有量の高い組成物の製造方法
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
DK0776214T3 (da) 1994-08-16 1999-11-29 Catharina Svanborg Antibakterialt præparat indeholdende multimert alfa-lactalbumin
US6159748A (en) 1995-03-13 2000-12-12 Affinitech, Ltd Evaluation of autoimmune diseases using a multiple parameter latex bead suspension and flow cytometry
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
JP2001524491A (ja) 1997-11-21 2001-12-04 カタリーナ・スヴァンボルイ ラクトアルブミン生産方法
GB9725126D0 (en) * 1997-11-27 1998-01-28 Svanborg Catharina Therapeutic agents
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
CA2404100A1 (en) 2000-03-24 2001-10-04 Filgen Biosciences, Inc. Therapeutic peptides having a motif that binds specifically to non-acetylated h3 and h4 histones for cancer therapy
AU2001261024A1 (en) * 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
GB0205347D0 (en) * 2002-03-07 2002-04-24 Svanborg Catharina Biologically active complex
GB0210464D0 (en) * 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
EP1727561A1 (en) * 2004-02-26 2006-12-06 HAMLET Pharma AB Lactalbumin for inhibiting angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anderson et al (1997) Biochemistry, 36:11648-11654 *
Svensson et al (2000) PNAS, 97(8):4221-4226 *

Also Published As

Publication number Publication date
EP1506233B1 (en) 2014-04-02
AU2003233116A1 (en) 2003-11-11
GB0210464D0 (en) 2002-06-12
JP2006500321A (ja) 2006-01-05
EP1506233B8 (en) 2014-09-24
US7270822B2 (en) 2007-09-18
WO2003095490A1 (en) 2003-11-20
DK1506233T3 (da) 2014-07-07
US7713533B2 (en) 2010-05-11
US20080167233A1 (en) 2008-07-10
CA2485223A1 (en) 2003-11-20
EP1506233A1 (en) 2005-02-16
US20060074017A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
US7713533B2 (en) Active complex of α-lactalbumin (HAMLET) and cofactor
Redl Human tear lipocalin
Siqueira et al. Small molecular weight proteins/peptides present in the in vivo formed human acquired enamel pellicle
US12331073B2 (en) Preparation of biologically active complexes
JP2023022318A (ja) ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物
US8796218B2 (en) Complex and production process
JP2023539476A (ja) アネキシンａ１のｎ末端ペプチド製剤及び方法
GB2052979A (en) Ophthalmological use for colostrum
CN100528223C (zh) 皮肤胶原产生促进剂
EP2944318A1 (en) Peptides and compositions thereof for improvement of glycaemic management in a mammal
CN113226350A (zh) 皮肤病治疗剂
JP2005530703A (ja) 生物学的に活性な複合体
Danielsen et al. Calcium-dependent and-independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH
JP2011503137A (ja) 新規のアルギニン置換ペプチド及びその使用
Ferranti et al. The “dark side” of β-lactoglobulin: Unedited structural features suggest unexpected functions
JP2024532407A (ja) ラクトフェリン組成物及び使用方法
JPH07309771A (ja) 非経口用抗腫瘍剤
CN118302187A (zh) 乳铁蛋白组合物和使用方法
Harrington Age and cataract-related degradation of crystallins in human lenses
CN116981442A (zh) 无使用稳定剂的含有天凡诺赛普特的稳定眼用组成物
JPH0881387A (ja) 創傷治癒剤
JP2005531539A (ja) ペプチド組成物
JPH07267994A (ja) 新規蛋白質及びその製造法
JPH0420289A (ja) 蛋白質

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HAMLET PHARMA AB

Free format text: FORMER APPLICANT(S): SVANBORG, CATHERINE

PC1 Assignment before grant (sect. 113)

Owner name: NYA HAMLET PHARMA AB

Free format text: FORMER APPLICANT(S): HAMLET PHARMA AB

TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 590 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME NYA HAMLET PHARMA AB, APPLICATION NO. 2003233116, UNDER INID (43) CORRECT PUBLICATION DATE TO READ 24 NOVEMBER 2003.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: HAMLET PHARMA AB

Free format text: FORMER OWNER WAS: NYA HAMLET PHARMA AB

MK14 Patent ceased section 143(a) (annual fees not paid) or expired